Open AccessPrognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Author(s) -
Sylvia Adams,
Robert J. Gray,
Sandra Demaria,
Lori J. Goldstein,
Edith A. Perez,
Lawrence N. Shulman,
Silvana Martino,
Molin Wang,
Vicky Jones,
Thomas J. Saphner,
Antonio C. Wolff,
William C. Wood,
Nancy E. Davidson,
George W. Sledge,
Joseph A. Sparano,
Sunil Badve
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2013.55.0491
Subject(s) - medicine , oncology , triple negative breast cancer , tumor infiltrating lymphocytes , breast cancer , adjuvant therapy , clinical endpoint , randomized controlled trial , cancer , immunotherapy
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative Oncology Group (ECOG).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom